Neoadjuvant SHR-A1811 showed similar pathologic complete response rates to the standard 4-drug regimen in patients with ...

为什么即使是相同的乳腺癌类型，不同的患者对新辅助化疗（neoadjuvant chemotherapy, NAC）的反应也大不相同？最近，来自荷兰癌症研究所的研究人员揭示了一个令人惊讶的答案：发情周期（estrous ...

Eligible patients were concurrently randomly assigned 1:1 to receive nivolumab (3 mg/kg once every 2 weeks; three cycles) plus ipilimumab (1 mg/kg; one dose at cycle 1 only) or platinum-doublet ...

Survival according to treatment group and complete pathologic response (pT0) in patients treated with either neoadjuvant MVAC and cystectomy or cystectomy alone. Hazard ratios for subgroups ...

Published in Clinical Cancer Research, results of a VHIO-led study underscore the potential of the RAD51 biomarker in ...

The investigators evaluated the feasibility and capacity of the RAD51 test to predict which patients with early-stage breast ...

Researchers found that receipt of neoadjuvant and adjuvant chemotherapy were associated with inadequate ovarian function suppression. Researchers say they have identified several factors that may be ...

In a propensity score-matched analysis, adjuvant therapy was significantly associated with a higher risk for all-cause and cancer-specific mortality and disease recurrence compared with ...

The addition of camrelizumab to platinum-containing intensive neoadjuvant chemotherapy improved pathologic complete response ...

Citation: Clinical trial finds adding camrelizumab to neoadjuvant chemo beneficial in triple-negative breast cancer (2024, December 16) retrieved 12 January 2025 from https://medicalxpress.com ...